News | June 08, 2009

Study Finds 3D Echo is a Stronger Outcome Predictor Than 2D

June 9, 2009 – Physicians can better predict potentially life-threatening cardiac events with real-time, three-dimensional echocardiography technology, according to a study released at the 20th Annual Scientific Sessions of the American Society of Echocardiography (ASE) in Washington, D.C.

The study concluded that 3D measurements could help guide management decisions on how to best treat the patient and better predict the patient’s chance of survival.

Left ventricular end systolic volume measured by 2D echocardiography is an important correlate of survival. Researchers sought to determine whether 3D echo was more predictive of outcome than 2D echo. The study included 535 patients referred for left ventricle assessment. Patients were assessed with 2D and 3D echocardiography.

Over four to five years, cardiac admission, incident heart failure, atrial fibrillation and all-cause mortality information was obtained in 461 of 504 patients with images suitable for measurement. The results showed 48 cardiac events (10 percent) including 34 deaths. Larger left ventricular end-systolic volume and lower ejection fraction were associated with worse outcome.

The addition of 2D echo end-systolic volume increased the association of clinical variables—renal disease, left ventricular impairment and age – with outcome, but 3D echo end-systolic volume increased the strength of association. Similarly, the incremental value of 2D echo ejection fraction was exceeded by 3D echo ejection fraction.

The study was conducted by Carly Jenkins, Tony Stanton and Thomas H. Marwick at University of Queensland in Woolloongabba, Australia.

For more information: www.asecho.org


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now